Contact
Search
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Investors & News
About
Stock information
Reports & Filings
News
Publications
Presentations
Events
Corporate Governance
Contact Us
Contact Us
Investors & News
Latest News
May 15, 2019
Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights
May 14, 2019
Stealth BioTherapeutics to Present at UBS Global Healthcare Conference
April 30, 2019
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
March 14, 2019
6-K Report of Foreign Private Issuer
HTML
February 14, 2019
Stealth BioTherapeutics Prospectus
HTML
Reports
Latest Presentations
May 03, 2019
Investor Presentation May 2019
Presentations
Events
May 21, 2019
UBS Global Healthcare Conference: 2:30 PM EDT
Financial Calendar
Media Relations
dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com
Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com
